

# WOAH Reference Laboratory Reports Activities 2025

This report has been submitted: 23 décembre 2025 20:17

## LABORATORY INFORMATION

<b>*Name of disease (or topic) for which you are a designated WOAH Reference Laboratory:</b>	Foot and mouth disease
<b>*Address of laboratory:</b>	TALCAHUANO 1660, MARTINEZ, BUENOS AIRES, CP 1640
<b>*Tel:</b>	+54-11 48.36.19.95
<b>*E-mail address:</b>	sgaldo@senasa.gob.ar
<b>Website:</b>	<a href="https://www.argentina.gob.ar/senasa/laboratorios">https://www.argentina.gob.ar/senasa/laboratorios</a>
<b>*Name (including Title) of Head of Laboratory (Responsible Official):</b>	Dr. Rodrigo Balzano Parodi MV, MSc DIRECTOR GENERAL DE LABORATORIO Y CONTROL TECNICO, DGLYCT, SENASA
<b>*Name (including Title and Position) of WOAH Reference Expert:</b>	Dr. Sabrina Galdo Novo, DVM,Esp, PhD COORDINATOR ANIMAL HEALTH, DLA , DGLYCT , SENASA
<b>*Which of the following defines your laboratory? Check all that apply:</b>	Governmental

## TOR1: DIAGNOSTIC METHODS

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in WOAH Manual (Yes/No)	Total number of test performed last year	
		Nationally	Internationally
Indirect diagnostic tests			
3 ABC ACTIVE SURVEILLANCE FOR EVIDENCE OF ABSCENCE OF VIRAL CIRCULATION AND CENTINEL ANIMALS FOR EXPORT REQUEST	Yes	472	3227
3 ABC DETERMINATION FROM PASSIVE SURVEILLANCE SUSPECTED CASES	Yes	64	0
EITB CONFIRMATIONS FROM 3 ABC ELISA TEST	Yes	13	0
VIAA	Yes	0	0
LP ELISA FOR POTENCY VACCINE CONTROL	Yes	0	0
VTN TEST FOR AB TITER DETERMINATION	Yes	1304	0
r1 value for vaccine matching assessmenT	Yes	37	0
Viral bovine and pig epithelia adaptation	Yes	2	0
PGP for in vivo challenge registration	Yes	6	0

Sabrina Galdo - -

PD50 for in vivo challenge certification	Yes	0	6
<b>Direct diagnostic tests</b>		<b>Nationally</b>	<b>Internationally</b>
SUSPECTED CASES FOR Q RT PCR DETECTION AND VIRAL ISOLATION	Yes	6	0
VP1 sequencing	No	24	12
p1 sequencing	No	3	0
cell viral isolations and amplification	Yes	62450	0

## TOR2: REFERENCE MATERIAL

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by WOA?

No

3. Did your laboratory supply standard reference reagents (nonWOAH-approved) and/or other diagnostic reagents to WOA Members?

Yes

Type of reagent available	Related diagnostic test	Produced/ provide	Amount supplied nationally (ml, mg)	Amount supplied internationally (ml, mg)	No. of recipient WOA Member Countries	Country of recipients
GUINEA PIG COMPLEMENT	COMPLEMENT FIXATION, for identity and innocuity - adventitious agents in master seeds, other	630 ml	600 ml	30 ml	1	PARAGUAY,
GUINEA PIG HYPERIMMUNE SERA OF DIFFERENT FMDV STRAINS	FOR COMPLEMENT FIXATION TEST AND AS SERA OF REFERENCE	260 ml	50 ML	20 ML	1	PARAGUAY,
RABBIT HEMOLISINE	COMPLEMENT FIXATION TEST	45 ML	2 ML	0	1	ARGENTINA,
FMDV VIRUS SUSPENSION FOR CEPARIUM MANTAINANCE	PD50 TESTS, PGP TEST, VIRUSNEUTRALIZATION TEST, VACCINE STUDIES, GENETIC CHARACTERIZATION AND ANTIGENIC CHARACTERIZATION	59900 ML	0	15 ML	2	ARGENTINA, UNITED KINGDOM,
ERA FOR PANEL REFERENCE	FOR AB VNT DETERMINATION, VACCINE MATCHING TEST, ANTIGENIC CHARACTERIZATION	200 ML	0	0	1	ARGENTINA,
BOVINE OR PIG ADAPTED INFECTED EPITHELIUM	AS REFERENCE REAGENT FOR VIRAL CHALLENGES	70 GR	0	6	1	ARGENTINA, CANADA,

4. Did your laboratory produce vaccines?

Yes

5. Did your laboratory supply vaccines to WOA Members?

No

## TOR3: NEW PROCEDURES

6. Did your laboratory develop new diagnostic methods for the designated pathogen or disease?

No

7. Did your laboratory validate diagnostic methods according to WOA Standards for the designated pathogen or disease?

No

8. Did your laboratory develop new vaccines for the designated pathogen or disease?

Sabrina Galdo - -

Yes

9. Did your laboratory validate vaccines according to WOAHP Standards for the designated pathogen or disease?

Yes

Name of the new vaccine developed	Description and References (Publication, website, etc)
SAT 1	CONFIDENTIAL mid scale experimental batch (SEE PUBLICATION AS INITIAL DOCUMENTATION GFRA SCIENT MEETING 2025 ISTANBUL, TURKEY)
SAT 3	CONFIDENTIAL mid scale experimental batch (SEE PUBLICATION AS INITIAL DOCUMENTATION GFRA SCIENT MEETING 2025 ISTANBUL, TURKEY)

## TOR4: DIAGNOSTIC TESTING FACILITIES

10. Did your laboratory carry out diagnostic testing for other WOAHP Members?

Yes

Name of WOAHP Member Country seeking assistance	Date	Which diagnostic test used	No. samples received for provision of diagnostic support	No. samples received for provision of confirmatory diagnoses
VIETNAM	2024-09-09	GENETIC CHARACTERIZATION, VACCINE MATCHING , PD50 TRIAL	12	12

11. Did your laboratory provide expert advice in technical consultancies on the request of an WOAHP Member?

Yes

Name of the WOAHP Member Country receiving a technical consultancy	Purpose	How the advice was provided
VIETNAM	BILLATERAL COLLABORATION TECHNICAL INFORMATION REQUEST	EXCHANGE OF PROPOSAL VIA OFFICIAL COMMUNICATION THROUGH THE CHANCELLERY EXCHANGE OF INFORMATION AND SOPs AND OTHER DOCUMENTS
THAILAND	BILLATERAL COOPERATION	EXCHANGE OF PROPOSAL VIA OFFICIAL COMMUNICATION THROUGH THE CHANCELLERY
QATAR	VACCINE CONTROL	LABORATORY VISIT/AUDIT
KAZAKHSTAN	VACCINE CONTROL - POST VACCINATION MONITORING AND IMMUNITY DETERMINATION	TRAINING AT SENASA'S LABORATORY
BANGLADESH	VACCINE CONTROL AND SURVEILLANCE	LABORATORY VISIT/AUDIT
SAUDI ARABIA	VACCINE CONTROL AND SURVEILLANCE	LABORATORY VISIT/AUDIT
PHILIPPINES	VACCINE CONTROL AND INFORMATICS SYSTEM	LABORATORY VISIT/AUDIT
INDONESIA	VACCINE CONTROL	LABORATORY VISIT/AUDIT

## TOR5: COLLABORATIVE SCIENTIFIC AND TECHNICAL STUDIES

12. Did your laboratory participate in international scientific studies in collaboration with WOAHP Members other than the own?

Yes

Title of the study	Duration	Purpose of the study	Partners (Institutions)	WOAHP Member Countries involved other than your country
Understanding cross- reactive responses between heterologous FMD virus strains in the bovine model	2 YEARS	Evaluation heterologous cross protection studies with different vaccine formulations	USDA , ARS, Plains Area Foreign Animal Disease Research Unit 40550 Route 25 Orient, New York 11957 2 Laboratorio de Referencia OMSA Para Fiebre Aftosa, Dirección de Laboratorio Animal, SENASA , CP1640 Martínez Buenos Aires, Argentina CVYVA	ARGENTINA UNITED STATES OF AMERICA

Sabrina Galdo - -

Animal reduction and replacement studies	5 YEARS	Evaluation correlacion of animal replacement of in vivo studies and animal reduction	INTA , Universidad de Buenos Aires , Facultad de Ciencias Exactas Dr. Guidobuono Santiago y Laboratorio de Referencia OMSA Para Fiebre Aftosa, Dirección de Laboratorio Animal, SENASA , CP1640 Martínez Buenos Aires, Argentina	ARGENTINA
--	---------	--	--	-----------

13. In exercising your activities, have you identified any regulatory research needs\* relevant for WOAHP?

No

## TOR6: EPIZOOLOGICAL DATA

14. Did your Laboratory collect epidemiological data relevant to international disease control?

Yes

If the answer is yes, please provide details of the data collected:

EPIDEMIOLOGICAL SURVEILLANCE DATA. PUBLISHED OFFICIALLY AT SENASA WEBSITE

15. Did your laboratory disseminate epidemiological data that had been processed and analysed?

No

16. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category and list the details in the box)

a) Articles published in peer-reviewed journals:

1

*Under review: A Highly potent SAT 2 Foot-and-mouth disease vaccine induces strong immune responses across species, with broad cross immunity against emerging middle eastern and african isolates (2017-2022)*

b) International conferences:

6

*Evaluation of FMDV type O field strains of lineages SEA- Mya98, ME-SA Ind 2001 and ME-SA Panasia, during 2019-2024 in Vietnam and its vaccine matching assessment with O1 Campos monovalent vaccine strain. GFRA scientific meeting, Istanbul, Turkiye 2025*

*Novel SAT 1/1 Foot-and-Mouth Disease Vaccine Strain Confers Broad Cross- Immunity Against emergent Middle Eastern and African Isolates . GFRA scientific meeting, Istanbul, Turkiye 2025*

*Development of a High-Potency Multivalent FMD Vaccine with Broad Immunological coverage Across Endemic Pools. GFRA scientific meeting, Istanbul, Turkiye 2025*

*"Right Tools, Real Impact: Evaluation and Use of FMD Vaccines and Diagnostics in the Field"; held on November 4–5, 2025, in Bangkok, Thailand,*

*PRESENTATION: Quality parameters for FMD vaccines*

*"Foot-and-Mouth Disease Prevention: Safeguarding Livestock, Livelihoods, and Economies" held on March 18–19, 2025, in Curitiba, Brazil,*

*XVI Jornadas Anuales de la Asociación Argentina de Inmunología Veterinaria y la IV Reunión de la Red Latinoamericana de Inmunología Veterinaria. Uruguay*

c) National conferences:

1

*Segundas jornadas una salud, Facultad de Cs Veterinarias Universidad de Buenos Aires, 4 al 6 de noviembre de 2025*

d) Other (Provide website address or link to appropriate information):

0

## TOR7: SCIENTIFIC AND TECHNICAL TRAINING

17. Did your laboratory provide scientific and technical training to laboratory personnel from other WOA Members?

Yes

a) Technical visit : 5

b) Seminars : 2

c) Hands-on training courses: 2

d) Internships (>1 month) 0

Type of technical training provided (a, b, c or d)	Country of origin of the expert(s) provided with training	No. participants from the corresponding country
C	KAZAKHSTAN	2
B	ARGENTINA	15
A	BANGLADESH	4
A	SAUDI ARABIA	4
A	PHILIPPINES	3
A	QATAR	3
A	INDONESIA	4
C	ARGENTINA	6

## TOR8: QUALITY ASSURANCE

18. Does your laboratory have a Quality Management System?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)	
ISO 17025	PDF	Certificado_de_acreditación.pdf

19. Is your quality management system accredited?

Yes

Test for which your laboratory is accredited	Accreditation body
3D Q RT PCR FOR FMDV DETECTION	ORGANISMO DE ACREDITACION ARGENTINO
ELISA 3ABC	ORGANISMO DE ACREDITACION ARGENTINO

20. Does your laboratory maintain a "biorisk management system" for the pathogen and the disease concerned?

Yes

A Biosecurity commission and biosecurity specialists in an individual technical department is guaranteed. A technical service department is also responsible for technical requisites. SOP's are elaborated and all the employees comply with the requirements according to ISO 17025 and following international standard recommendations.

## TOR9: SCIENTIFIC MEETINGS

21. Did your laboratory organise scientific meetings related to the pathogen in question on behalf of WOA?

No

22. Did your laboratory participate in scientific meetings related to the pathogen in question on behalf of WOA?

Yes

Sabrina Galdo - -

Title of event	Date	location	Role (speaker, presenting poster, short communications)	Title of the work presented
GFRA SCIENTIFIC MEETING	2025-10-21	ISTANBUL TURKIYE	POSTER	Evaluation of FMDV type O field strains of lineages SEA-Mya98, ME-SA Ind 2001 and ME-SA Panasia, during 2019-2024 in Vietnam and its vaccine matching assessment with O1 Campos monovalent vaccine strain
GFRA SCIENTIFIC MEETING	2025-10-21	ISTANBUL TURKIYE	POSTER	Competitive interactions within mixtures of infectious clones A01Lc and A01NLc: impact on FMDV lethality in mice
GFRA SCIENTIFIC MEETING	2025-10-21	ISTANBUL TURKIYE	POSTER	Novel SAT 1/I Foot-and-Mouth Disease Vaccine Strain Confers Broad Cross- Immunity Against emergent Middle Eastern and African Isolates
GFRA SCIENTIFIC MEETING	2025-10-21	ISTANBUL TURKIYE	SPEAKER THE LABORATORY PARTICIPATED BUT THE SPEACKER WAS DR. SCIAN	Development of a High-Potency Multivalent FMD Vaccine with Broad immunological coverage Across Endemic Pools
FMDV NETWORK MEETING 2025	2025-10-23	ISTANBUL TURKIYE	SPEAKER	ACTIVITIES FOR WOAHP REFERENCE LABORATORY SENASA ARGENTINA 2025
TAFS FORUM	2025-11-05	BANGKOK THAILAND	SPEAKER DR ANA TAFFAREL	Quality parameters for FMD vaccines
GFRA WEBINAR	2025-02-13	VIRTUAL	PARTICIPANT	Analysis of FMDv Vaccine Quality Using Single Domain Antibodies Dr. Michiel Harmsen.
GFRA WEBINAR	2025-03-19	VIRTUAL	PARTICIPANT	Foot-and-Mouth Disease in South America: Lessons Learned and Future Challenges Mariano Perez-Filgueira
GFRA WEBINAR	2025-04-16	VIRTUAL	PARTICIPANT	"Current Research and Situation Analysis of Foot-and-Mouth Disease in East Africa." Dr Susan Kerfua
GFRA WEBINAR	2025-05-15	VIRTUAL	PARTICIPANT	"FMDV Pathogenesis in Different Domestic Livestock Hosts: Recognizing the Importance of Species-Specific Considerations." Dr Caroline Stendfeldt
GFRA WEBINAR	2025-07-17	VIRTUAL	PARTICIPANT	FMD in Germany 2025. Dr Michael Eschbaumer
GFRA WEBINAR	2025-09-09	VIRTUAL	PARTICIPANT	GFRAAC Webinar with Dr. Mohamed Fawzy
IVSRN	2025-07-18	VIRTUAL	PARTICIPANT SPEAKER	Virtual meeting of the International Vaccine Strategic Reserve Network (IVSRN)
IVRSN	2025-11-10	VIRTUAL	PARTICIPANT SPEAKER	International Vaccine Strategic Reserves Network (IVSRN) meeting
COSALFA BIOSECURITY AND BIOSAFETY COMISSION	2025-08-19	VIRTUAL	PARTICIPATS (ENG E ROQUEIRO AND VET ANA TAFFAREL)	DEFINITION OF TERMS OF REFERENCE OF THE COMISSION, PENDING AUDITS

## TOR10: NETWORK WITH WOAHP REFERENCE LABORATORIES

Sabrina Galdo - -

23. Did your laboratory exchange information with other WOA Reference Laboratories designated for the same pathogen or disease?

Yes

24. Are you a member of a network of WOA Reference Laboratories designated for the same pathogen?

Yes

NETWORK/DISEASE	ROLE OF YOUR LABORATORY (PARTICIPANT, ORGANISER, ETC)	NO. PARTICIPANTS	PARTICIPATING WOA REF. LABS
IVSRN	PARTICIPANT	13	MOST OF ALL THE WOA REF LABORATORIES. HEAD 2025, DR CHARLES N FON CFIA CANADA
FMDV WOA REF LAB NETWORK	PARTICIPANT	16	<a href="https://www.foot-and-mouth.org/">https://www.foot-and-mouth.org/</a>
BIOSECURITY AND BIOSAFETY COMMISSION COSALFA	PARTICIPANT	6	IN JOINT WITH PANAFTOA

25. Did you organise or participate in inter-laboratory proficiency tests with WOA Reference Laboratories designated for the same pathogen during the past 2 years?

Yes

Purpose of the proficiency test:	Role of your Reference Laboratory (organiser/ participant)	No. participating Laboratories	Participating WOA Ref. Labs/ organising WOA Ref Lab
024/2025 Foot-and-Mouth Disease Proficiency Testing Scheme (Phase XXXVI),	PARTICIPANT	RESULTS NOT REVEALED YET	RESULTS NOT REVEALED YET
15ª Ronda del Ensayo de Proficiencia – 2025 (PEP-2025). PANFTOSA PAHO	PARTICIPANT	RESULTS NOT REVEALED YET	RESULTS NOT REVEALED YET

26. Did your laboratory collaborate with other WOA Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

Yes

Title of the project or contract	Scope	Name(s) of relevant WOA Reference Laboratories
IN VIVO TRIALS INTERCHANGE OF REFERENCE MATERIAL	IN VIVO TRIALS INTERCHANGE OF REFERENCE MATERIAL	PIRBRIGHT UK LELYSTAD NETHERLANDS ANSES FRANCE

## TOR11: OTHER INTERLABORATORY PROFICIENCY TESTING

27. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than WOA Reference Laboratories for the same pathogen during the past 2 years?

No

NO PARTICIPATION WITH NON WOA MEMBERS FOR INTERLABORATORIES

## TOR12: EXPERT CONSULTANTS

28. Did your laboratory place expert consultants at the disposal of WOA?

Yes

Kind of consultancy	Location	Subject (facultative)
REVIEW OF CHAPTER 3.1.8	VIRTUALLY	REVIEW OF CHAPTER FOOT AND MOUTH DISEASE 3.1.8

29. Additional comments regarding your report:

Yes

HIGH DIFFICULTY IN FULLFILLING ALL THE TERMS OF REFERENCE, SINCE SENASA DOES NOT SUPPLY A SPECIAL BUDGET OR STAFF FOR THE SUSTAINABILITY OF THE REFERENCE. THIS IS WHY MANY PUBLICATIONS ARE STILL PENDING AND SOME ACTIVITIES IN RELATION TO RESEARCH ARE DELAYED BECAUSE THE STAFF THAT COMPLIES WITH ACTIVITIES FOR THE REFERENCE IS ALSO THE SAME PEOPLE THAT COVERS THE GOVERNMENTAL ACTIVITIES  
THIS REPORTS COMPLIES INFORMATION UNTIL NOVEMBER 2025 SINCE THE YEAR HAS NOT CLOSED